Quidel Corporation (NASDAQ:QDEL) is reporting third quarter financial results on Thursday 29th October 2020, after market close.
According to analysts surveyed by Thomson Reuters, QDEL is expected to report 3Q20 income of $ 4.75 per share from revenue of $ 450.39 million.
For the full year, analysts anticipate top line of $ 1519.15 million, while looking forward to income of $ 15.73 per share bottom line.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 475.00 million ~ $ 477.00 million
Click Here For More Historical Outlooks Of Quidel Corporation
Previous Quarter Performance
Quidel Corporation disclosed income for the second quarter of $ 1.86 per share, from the revenue of $ 201.75 million. The quarterly earnings 416.67 percent while revenues boosted 86.87 percent compared with the same quarter last year.
According to street consensus, QDEL was expected to report 2Q20 income of $ 1.09 per share from revenue of $ 189.79 million. The bottom line results beat street analysts by $ 0.77 or 70.64 percent, at the same time, top line results outshined analysts by $ 11.96 million or 6.30 percent.
Stock Performance
Shares of Quidel Corporation traded low $ -9.81 or -3.59 percent on Wednesday, reaching $ 263.79 with volume of 642.90 thousand shares. Quidel Corporation has traded high as $ 274.91 and has cracked $ 261.02 on the downward trend
According to the previous trading day, closing price of $ 263.79, representing a 393.68 % increase from the 52 week low of $ 55.42 and a 10.8 % decrease over the 52 week high of $ 306.72.
The company has a market capital of $ 11.74 billion and is part of the Healthcare sector and Diagnostics & Research industry.
Conference Call
Quidel Corporation will be hosting a conference call at 5:00 PM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.quidel.com
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, womens and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. It also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine.
